DB 1324
Alternative Names: DB-1324Latest Information Update: 10 Dec 2025
At a glance
- Originator Duality Biologics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 04 Dec 2025 Duality Biologics in collaboration with GlaxoSmithKline plans a phase I/II trial for Gastrointestinal cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA and Australia (IV) (NCT07263594)
- 03 Dec 2024 Duality Biologics and GSK entered into an option agreement for rights of DB 1324 in Worldwide excluding China, Hong Kong, Macau for Gastrointestinal cancer
- 03 Dec 2024 Preclinical trials in Gastrointestinal cancer in China (Parenteral) before December 2024